The IMDL is a specialized facility at the UPCI dedicated to the state-of- the-art evaluation of immune responses in patients with cancer and generation of cellular products for therapy. In its functions as Core B for this program, the IMDL will be responsible for generation, evaluation and genetic modification of human dendritic cells (DC) for four the five projects. For Project 1, the IMDL will generate human DC from peripheral blood of normal donors, characterize for the phenotype and function and perform pre-clinical studies of loading them with peptides. For Project 3, the IMDL will generate human DC from peripheral blood of normal donors or patients and attempt to tolerize them through transduction of immunosuppressive genes(e.g., v-IL10, TGF-beta). For Projects 4 and 5, cultured human DC will be pulsed with tumor antigens or peptides and genetically engineered by transfer of CD40L or melanoma-specific antigen genes to optimize co-stimulatory DC functions. Core B will be responsible for procurement and processing of human tissues and body fluids for experimental protocols or for use in clinical trials. I will also prepare autologous DC for human clinical trials under the good laboratory practice and safety conditions acceptable for transfer of ex vivo cellular products to humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-03
Application #
6300529
Study Section
Project Start
2000-03-01
Project End
2000-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2000
Total Cost
$197,104
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications